Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oncolytics Biotech Inc (NQ: ONCY )

1.720 +0.060 (+3.61%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 228,499
Open 1.700
Bid (Size) 1.750 (1)
Ask (Size) 1.850 (50)
Prev. Close 1.660
Today's Range 1.640 - 1.720
52wk Range 0.8021 - 2.280
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:JAZZ),(NASDAQ:GERN),(NASDAQ:INAB),(NASDAQ:VCYT) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Expert Ratings for Oncolytics Biotech
 
Via Benzinga

Performance

YTD
+7.50%
+7.50%
1 Month
+6.17%
+6.17%
3 Month
+8.18%
+8.18%
6 Month
-7.03%
-7.03%
1 Year
+57.80%
+57.80%

More News

Read More
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting’s Oral Presentations
Via FinancialNewsMedia
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2023
Via Benzinga
Why Hibbett Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Oncolytics Biotech: Q1 Earnings Insights
Via Benzinga
Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer
Via FinancialNewsMedia
Oncolytics Biotech's Earnings: A Preview
Via Benzinga
The Global Metastatic Breast Cancer Treatment Market Expected To Reach $31 Billion By 2028
Via FinancialNewsMedia
Rise in Biotech Innovations Generating Hope as Pancreatic Cancer Survival Rates Climb
Via FinancialNewsMedia
Exposures Product Safety
Global Breast Cancer Market Size Projected To Hit $70 Billion in Revenues By 2030
Via FinancialNewsMedia
Earnings Scheduled For March 3, 2023
Via Benzinga
Oncolytics Biotech’s® Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast
Via FinancialNewsMedia
Earnings Scheduled For May 5, 2023
Via Benzinga
Oncolytics Biotech's Earnings: A Preview
Via Benzinga
Biotechs Race for New Treatments as Breast Cancer Therapeutics Market Could Reach $15 Billion by 2028
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
Nasdaq Turns Lower; Dow Tumbles Over 300 Points
Via Benzinga
Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That’s Heating Up
Via FinancialNewsMedia
Exposures Product Safety
Why Dollar General Shares Are Trading Lower By Over 8%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Oncolytics Biotech® Receives FDA Fast Track Designation for the Treatment of Advanced/Metastatic Pancreatic Cancer
Via FinancialNewsMedia
Exposures Product Safety
Optimism Building for Advancing Pancreatic Cancer Treatment Therapies
Via FinancialNewsMedia
Exposures Product Safety
Big Developments Set to be Unveiled at This Year’s San Antonio Breast Cancer Symposium (SABCS)
Via FinancialNewsMedia
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer
Via FinancialNewsMedia
Topics Death
Exposures Death
Biotech Sector Gaining Wins Against Pancreatic Cancer with Early Detection and New Therapies
Via FinancialNewsMedia
Biotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer
Via FinancialNewsMedia
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.